CXCR3 and neoplasm: We found that mice treated with bintrafusp alfa and anti-CXCR3 had significantly worse survival (P = 0.0006, n = 10, 13) and increased tumor volume (P < 0.0001 on day 27, n = 10, 13) relative to mice treated with bintrafusp alfa alone (Fig. 7a, b).